1. Home
  2. BRID vs IMUX Comparison

BRID vs IMUX Comparison

Compare BRID & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgford Foods Corporation

BRID

Bridgford Foods Corporation

N/A

Current Price

$7.94

Market Cap

72.8M

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.66

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRID
IMUX
Founded
1932
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
85.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BRID
IMUX
Price
$7.94
$0.66
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$6.00
AVG Volume (30 Days)
3.5K
1.2M
Earning Date
08-22-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$227,364,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.24
$0.56
52 Week High
$10.83
$1.42

Technical Indicators

Market Signals
Indicator
BRID
IMUX
Relative Strength Index (RSI) 55.33 38.75
Support Level $7.40 $0.67
Resistance Level $7.98 $0.72
Average True Range (ATR) 0.20 0.05
MACD 0.05 -0.00
Stochastic Oscillator 95.26 4.08

Price Performance

Historical Comparison
BRID
IMUX

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: